Patents by Inventor Sharon Amit

Sharon Amit has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8263326
    Abstract: Compositions and methods for modulating the activation of nuclear factor ?B (NF-?B) are provided. The compositions comprise one or more agents that modulate ubiquitination of phosphorylated I?B? and/or I?B?. Such compositions may be used for treating diseases associated with NF-?B activation. Modulating agents include human E3 ubiquitin ligases, antibodies thereto and variants thereof, as well as related proteins.
    Type: Grant
    Filed: August 8, 2008
    Date of Patent: September 11, 2012
    Assignee: Signal Pharmaceuticals, LLC
    Inventors: Anthony M. Manning, Frank Mercurio, Sharon Amit, Yinon Ben-Neriah, Matti Davis, Ada Hatzubai, Avraham Yaron, Irit Alkalay, Aaron Ciechanover
  • Publication number: 20090233855
    Abstract: Compositions and methods for modulating the activation of nuclear factor ?B (NF-?B) are provided. The compositions comprise one or more agents that modulate ubiquitination of phosphorylated I?B? and/or I?B? Such compositions may be used for treating diseases associated with NF-?B activation. Modulating agents include human E3 ubiquitin ligases, antibodies thereto and variants thereof, as well as related proteins.
    Type: Application
    Filed: August 8, 2008
    Publication date: September 17, 2009
    Inventors: Anthony M. MANNING, Frank Mercurio, Sharon Amit, Yinon Ben-Neriah, Matti Davis, Ada Hatzubai, Avraham Yaron, Irit Alkalay, Aaron Ciechanover
  • Publication number: 20070208167
    Abstract: Compositions and methods for modulating the activation of nuclear factor ?B (NF-?B) are provided. The compositions comprise one or more agents that modulate ubiquitination of phosphorylated I?B? and/or I?B?. Such compositions may be used for treating diseases associated with NF-?B activation. Modulating agents include human E3 ubiquitin ligases, antibodies thereto and variants thereof, as well as related proteins.
    Type: Application
    Filed: January 25, 2007
    Publication date: September 6, 2007
    Inventors: Anthony Manning, Frank Mercurio, Sharon Amit, Yinon Ben-Neriah, Matti Davis, Ada Hatzubai, Avraham Yaron, Irit Alkalay, Aaron Ciechanover
  • Publication number: 20050171005
    Abstract: The present invention provides modulators of ?-catenin phosphorylation. More specifically, the present invention provides inhibitors and enhancers of ?-catenin Serine 45 (S45) phosphorylation. Examples of inhibitors provided by the invention are the proteins Dishevelled (Dvl), Wnt, phosphatase PP2A and CKI7. Examples of enhancers of beta-catenin phosphorylation are phosphatase inhibitors and proteins that promote ?-catenin acetylation, like FRAT1. In addition, the present invention provides compositions and uses of the modulators of the invention, specifically for the treatment of cancer, as well as a method for screening such modulators.
    Type: Application
    Filed: October 25, 2004
    Publication date: August 4, 2005
    Inventors: Yinon Ben-Neriah, Irit Alkalay, Sharon Amit, Yaara Birman, Ada Hatzubai
  • Publication number: 20040203098
    Abstract: Compositions and methods for modulating the activation of nuclear factor &kgr;B (NF-&kgr;B) are provided. The compositions comprise one or more agents that modulate ubiquitination of phosphorylated I&kgr;B&agr; and/or I&kgr;B&bgr;. Such compositions may be used for treating diseases associated with NF-&kgr;B activation. Modulating agents include human E3 ubiquitin ligases, antibodies thereto and variants thereof, as well as related proteins.
    Type: Application
    Filed: September 19, 2003
    Publication date: October 14, 2004
    Inventors: Anthony M. Manning, Frank Mercurio, Sharon Amit, Yinon Ben-Neriah, Matti Davis, Ada Hatzubai, Avraham Yaron, Irit Alkalay, Aaron Ciechanover
  • Patent number: 6656713
    Abstract: Compositions and methods for modulating the activation of nuclear factor &kgr;B (NF-&kgr;B) are provided. The compositions comprise one or more agents that modulate ubiquitination of phosphorylated I&kgr;B&agr; and/or I&kgr;B&bgr;. Such compositions may be used for treating diseases associated with NF-&kgr;B activation. Modulating agents include human E3 ubiquitin ligases, antibodies thereto and variants thereof, as well as related proteins.
    Type: Grant
    Filed: April 9, 2001
    Date of Patent: December 2, 2003
    Assignee: Signal Pharmaceuticals, Inc.
    Inventors: Anthony M. Manning, Frank Mercurio, Sharon Amit, Yinon Ben-Neriah, Matti Davis, Ada Hatzubai, Avraham Yaron, Irit Alkalay, Aaron Ciechanover
  • Publication number: 20030166587
    Abstract: Compositions and methods for modulating the activation of nuclear factor &kgr;B (NF-&kgr;B) are provided. The compositions comprise one or more agents that modulate ubiquitination of phosphorylated I&kgr;B&agr; and/or I&kgr;B&bgr;. Such compositions may be used for treating diseases associated with NF-&kgr;B activation. Modulating agents include human E3 ubiquitin ligases, antibodies thereto and variants thereof, as well as related proteins.
    Type: Application
    Filed: April 9, 2001
    Publication date: September 4, 2003
    Inventors: Anthony M. Manning, Frank Mercurio, Sharon Amit, Yinon Ben-Neriah, Matti Davis, Ada Hatzubai, Avraham Yaron, Irit Alkalay, Aaron Ciechanover